CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present at three events during the month of December.
- Oppenheimer 25th Annual Healthcare Conference, December 10, 2014, New York, NY
- Merrimack Analyst Day, December 18, 2014, New York, NY
- 2014 San Antonio Breast Cancer Symposium, December 9-13, 2014, San Antonio, TX
Oppenheimer 25th Annual Healthcare Conference
Wednesday, December 10, 2014 - 3:20 p.m. ET
Crowne Plaza Hotel, New York, NY
- Edward Stewart, Senior Vice President, Commercial, is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference. A live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation.
Merrimack 2014 Analyst Day
Thursday, December 18, 2014 - 9:00 a.m. to 1:00 p.m. ET
New York, NY
- Members of Merrimack's management and commercial teams will review the company's commercialization and development strategy for MM-398. MM-398 is an investigational drug candidate for which Merrimack is preparing a New Drug Application in the United States for the treatment of patients with metastatic pancreatic cancer previously treated with a gemcitabine-based therapy.
- Presentations will also include development plans for the rest of Merrimack's late stage pipeline.
- A live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for six weeks following the presentation.
San Antonio Breast Cancer Symposium
December 9-13, 2014
Henry B. Gonzalez Convention Center, San Antonio, TX
- Merrimack will present research on three of its therapeutic candidates at the 2014 San Antonio Breast Cancer Symposium, December 9-13, 2014 in San Antonio, TX.
Poster Sessions:
MM-302
- Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by 64Cu-MM-302 PET/CT (Abstract #P4-15-04)
Poster Session 4: Treatment – HER2-Targeted Therapy
Friday, December 12, 2014
7:30-9:00 a.m. CT, Exhibit Halls A-B
- HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pertuzumab and trastuzumab emtansine (T-DM1) (Abstract #OT3-1-10)
Poster Session OT3: Ongoing Clinical Trials 3 – Her2
Friday, December 12, 2014
5:00-7:00 p.m. CT, Exhibit Halls A-B
- Tumor priming with cyclophosphamide for enhanced tumor delivery, penetration and anti-tumor activity of MM-302, HER2-targeted liposomal doxorubicin (Abstract #P6-11-05)
Poster Session 6: Treatment – New Drugs and Treatment Strategies
Saturday, December 13, 2014
7:30-9:00 a.m. CT, Exhibit Hall C
MM-398
- Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI) (Abstract #P5-01-06)
Poster Session 5: Detection and Diagnosis – Molecular, Functional, and Novel Imaging
Friday, December 12, 2014
5:00-7:00 p.m. CT, Exhibit Halls A-B
MM-121
- A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer (Abstract #P3-11-03)
Poster Session 3: Treatment – Neoadjuvant Chemotherapy
Thursday, December 11, 2014
5:00-7:00 p.m. CT, Exhibit Halls A-B
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and three additional candidates in late stage preclinical development. Merrimack's lead product candidate, MM-398, recently completed a Phase 3 clinical trial in post-gemcitabine pancreatic cancer. Based on the results of this clinical trial, Merrimack is currently preparing a New Drug Application for MM-398. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.